



16 February 2021

Sydney, Australia

Lapsing of Unlisted Scientific Advisory Board (SAB) Options

Sydney, 16 February 2021: Nyrada Inc (ASX: NYR) advises that the following unlisted options have lapsed on 15 February 2021:

ASX Code	Number	Description
NYRAI	645,000	Unlisted SAB Options exercisable at \$0.26 (ie 130% of the IPO Price), expiring on 15 February 2021.

Following the exercising of 1,355,000 of these options as announced in the Appendix 2A released on 16 February 2021, and the lapsing of 645,000 of these options further to the above, the updated capital structure table for unquoted securities is as follows:

ASX security code and description	Total number of +securities on issue
Chess Depository Interests Restricted (NYRAB)	33,105,853
Warrants Expiring 30-Jun-2024 Restricted (NYRAC)	8,000,000
Performance Shares Restricted (NYRAE)	18,000,000
Option Expiring 16-Jan-2023 Restricted (NYRAG)	800,000
Option Expiring Var Dates Restricted Ex Var Prices (NYRAH)	30,600,000
Option Expiring Various Dates Ex Various Prices (NYRAI)	2,900,000
Exercising of options - Appendix 2A dated 16 February 2021	-1,355,000
Lapsing of options – this release	<u>-645,000</u>
	900,000

About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited.

www.nyrada.com

Authorised by John Moore, Non-Executive Chairman, on behalf of the Board.

**Investor & Corporate Enquiries:**

Laura Vize
Investor Relations Manager
T: 0417 026 056
E: info@nyrada.com

Company Secretary:

David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com

Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.